Separately, PD-1+ αβ T cells have been shown to provide the proliferative burst in response to anti-PD-1 treatment which is associated with favourable therapeutic responses in patients with cancer [86, 90] and there is increasing evidence this may also be true for Vδ1 T cells [31, 91]. Here, PDCD1 is linked to cancer.